AFMD Affimed N.V.

2.28
-0.03  -1%
Previous Close 2.31
Open 2.33
Price To Book 7.12
Market Cap 173,799,658
Shares 76,227,920
Volume 921,924
Short Ratio
Av. Daily Volume 610,005
Stock charts supplied by TradingView

NewsSee all news

  1. Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

    FOR IMMEDIATE RELEASE First patient dosed in company's first registration-directed study of AFM13 for patients with relapsed/refractory peripheral T cell lymphoma (pTCL)FDA clearance of investigational new drug

  2. Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

      Heidelberg, Germany, November 14, 2019 – Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host

  3. Affimed to Present at the Jefferies 2019 London Healthcare Conference

    Heidelberg, Germany, November 14, 2019 – Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi

  4. Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters' Option to Purchase Additional Shares

    FOR IMMEDIATE RELEASE Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters' Option to Purchase Additional Shares Heidelberg, Germany, November 13, 2019 – Affimed N.V. ("Affimed"

  5. Affimed Announces Pricing of Public Offering of Common Shares

    Heidelberg, Germany, November 8, 2019 – Affimed N.V. ("Affimed" or the "Company") (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
AFM13
Hodgkin Lymphoma - Cancer
Phase 2 dosing has been initiated - noted November 19, 2019.
AFM13
CD30-positive peripheral T cell lymphoma (PTCL)
Phase 1 program terminated - noted May 22, 2019.
AFM11
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
Phase 1/2a trial to commence 1Q 2020.
AFM24
EGFR-expressing solid tumors

Latest News

  1. Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

    FOR IMMEDIATE RELEASE First patient dosed in company's first registration-directed study of AFM13 for patients with relapsed/refractory peripheral T cell lymphoma (pTCL)FDA clearance of investigational new drug

  2. Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

      Heidelberg, Germany, November 14, 2019 – Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host

  3. Affimed to Present at the Jefferies 2019 London Healthcare Conference

    Heidelberg, Germany, November 14, 2019 – Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi

  4. Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters' Option to Purchase Additional Shares

    FOR IMMEDIATE RELEASE Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters' Option to Purchase Additional Shares Heidelberg, Germany, November 13, 2019 – Affimed N.V. ("Affimed"

  5. Affimed Announces Pricing of Public Offering of Common Shares

    Heidelberg, Germany, November 8, 2019 – Affimed N.V. ("Affimed" or the "Company") (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer,

  6. Affimed Announces Proposed Public Offering of Common Shares

    Heidelberg, Germany, November 7, 2019 – Affimed N.V. ("Affimed" or the "Company") (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today

  7. Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

    Genentech exercises its final option for an exclusive target selection under ongoing, multi-program strategic oncology collaborationThe exclusive target selection triggers a payment in an undisclosed amount to Affimed

  8. Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

    Activation of innate immunity to target EGFR-expressing solid tumors has potential to address limitations associated with currently available EGFR-targeted therapiesInitiation of Phase 1/2a clinical trial expected in

  9. Affimed Reports Progress on Key Clinical Development Programs

      IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumorsFDA clearance of IND for first clinical study of a stable complex of AFM13 pre-mixed with cord

  10. Affimed to Participate in Investor Conferences in September

      Heidelberg, Germany, August 28, 2019 - Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced its